Journal
JOURNAL OF CLINICAL HYPERTENSION
Volume 15, Issue 6, Pages 435-442Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1751-7176.2012.00701.x
Keywords
-
Categories
Funding
- Novartis
- Boehringer Ingelheim
- Forest
Ask authors/readers for more resources
J Clin Hypertens (Greenwich). 2013; 15:435-442 (c) 2012 Wiley Periodicals, Inc. Allopurinol is a potent xanthine oxidase inhibitor that is used in hyperuricemic patients to prevent gout. It has also been shown to decrease cardiovascular complications in a myriad of cardiovascular conditions. However, studies have reported conflicting evidence on its effects on blood pressure (BP). A systematic review was conducted using Medline, PubMed, Embase, and the Cochrane Library for all the longitudinal studies that assessed the efficacy of allopurinol on systolic and diastolic BP. A total of 10 clinical studies with 738 participants were included in the analysis. Compared with the control group, systolic BP decreased by 3.3mmHg (95% confidence interval [CI], 1.4-5.3mmHg; P=.001) and diastolic BP decreased by 1.3mmHg (95% CI, 0.1-2.5mmHg; P=.03) in patients treated with allopurinol. When analysis was restricted to the higher-quality randomized controlled trials, similar changes in systolic and diastolic BPs were found: 3.3mmHg (95% CI, 0.8-5.8mmHg; P<.001) and 1.4mmHg (95% CI, 0.1-2.7mmHg; P=.04), respectively. Allopurinol is associated with a small but significant reduction in BP. This effect can be potentially exploited to aid in controlling BP in hypertensive patients with hyperuricemia. (C) 2012 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available